Trials / Suspended
SuspendedNCT03894345
Prazosin Use in Adults With Anxiety Disorders
Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Manitoba · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Prazosin has shown effectiveness in treating Post-Traumatic Stress Disorder through improving sleep quality and global functioning. Given the significant evidence for its utility in treating PTSD, in combination with the fact that many anxiety symptoms overlap with PTSD (e.g.insomnia, hyperarousal, and irritability), it is essential to evaluate its potential effectiveness in treating symptoms of other anxiety disorder and patient tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prazosin | Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy |
Timeline
- Start date
- 2019-05-24
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2019-03-28
- Last updated
- 2022-11-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03894345. Inclusion in this directory is not an endorsement.